News for MaxCyte Stock (MXCT)

MaxCyte Signs Strategic Platform License with Be Biopharma to Support the Development of Engineered B Cell Medicines (BCMs)

GlobeNewsWire • 04/02/24

MaxCyte, Inc. (MXCT) Q4 2023 Earnings Call Transcript

Seeking Alpha • 03/13/24

MaxCyte Reports Fourth Quarter and Full Year 2023 Financial Results and Reiterates 2024 Guidance

GlobeNewsWire • 03/12/24

MaxCyte Initiates Full Year 2024 Guidance and Reaffirms 2023 Preliminary Results

GlobeNewsWire • 03/04/24

MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences

GlobeNewsWire • 02/09/24

MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen's Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers

GlobeNewsWire • 01/30/24

MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs

GlobeNewsWire • 01/23/24

MaxCyte Announces Preliminary Unaudited Fourth Quarter and Full Year 2023 Financial Results

GlobeNewsWire • 01/08/24

MaxCyte and Lion TCR form Partnership to Support Global Expansion of Lion TCR's TCR-T Cell Pipeline

GlobeNewsWire • 01/03/24

MaxCyte Confirms Appointment of Maher Masoud as President, Chief Executive Officer and Director

GlobeNewsWire • 01/02/24

MaxCyte Announces CEO Transition and Updates Revenue Guidance for 2023

GlobeNewsWire • 12/11/23

MaxCyte May Benefit From Potential Gene Therapy Approval

Seeking Alpha • 11/27/23

MaxCyte Joins the Alliance for mRNA Medicines (AMM) as a Founding Member

GlobeNewsWire • 11/16/23

MaxCyte, Inc. (MXCT) Q3 2023 Earnings Call Transcript

Seeking Alpha • 11/09/23

MaxCyte Reports Third Quarter 2023 Financial Results and Reiterates Full Year 2023 Revenue Guidance

GlobeNewsWire • 11/08/23

Penny Stocks To Buy This Week? Analysts Like These 3

PennyStocks • 10/09/23

Why Shares of MaxCyte Are Plummeting on Thursday

The Motley Fool • 10/05/23

Why Is MaxCyte (MXCT) Stock Down 21% Today?

InvestorPlace • 10/05/23

MaxCyte Announces Preliminary Third Quarter 2023 Revenue and Updates Full Year 2023 Revenue Guidance

GlobeNewsWire • 10/04/23

MaxCyte Appoints Ali Soleymannezhad as Executive Vice President of Bioprocessing

GlobeNewsWire • 09/06/23

MaxCyte to Participate in Baird Global Healthcare Conference

GlobeNewsWire • 09/05/23

MaxCyte, Inc. (MXCT) Q2 2023 Earnings Call Transcript

Seeking Alpha • 08/10/23

MaxCyte Reports Second Quarter and Half-Year 2023 Financial Results and Updates Full Year 2023 Guidance

GlobeNewsWire • 08/09/23

MaxCyte Signs Strategic Platform License with Prime Medicine to Advance Next-Generation Gene Editing Therapies for Patients

GlobeNewsWire • 08/01/23

MaxCyte to Report Second Quarter 2023 Financial Results on August 9, 2023

GlobeNewsWire • 07/13/23